Hematologic safety of (177)Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer

BACKGROUND: Myelosuppression is a potential dose-limiting factor in radioligand therapy (RLT). This study aims to investigate occurrence, severity and reversibility of hematotoxic adverse events in patients undergoing RLT with (177)Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCR...

Descripción completa

Detalles Bibliográficos
Autores principales: Groener, Daniel, Nguyen, Cam Tu, Baumgarten, Justus, Bockisch, Benjamin, Davis, Karen, Happel, Christian, Mader, Nicolai, Nguyen Ngoc, Christina, Wichert, Jennifer, Banek, Severine, Mandel, Philipp, Chun, Felix K. H., Tselis, Nikolaos, Grünwald, Frank, Sabet, Amir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254689/
https://www.ncbi.nlm.nih.gov/pubmed/34216290
http://dx.doi.org/10.1186/s13550-021-00805-7

Ejemplares similares

Ejemplares similares